A laboratory study published in the Journal of Clinical Microbiology has quantified how far blood suppresses real-time quaking-induced conversion (RT-QuIC), the seed amplification assay that, in people, is run on cerebrospinal fluid rather than blood. Robert B. Piel and David A. Schneider, of Washington State University and the United States Department of Agriculture's Animal Disease Research Unit in Pullman, seeded reactions with brain homogenate from scrapie-positive sheep and added haem (spelled heme in the paper) in three forms: free hemin, haem bound in haemoglobin, and haem as it occurs in whole blood. At matched haem concentrations, whole blood inhibited the reaction most, haemoglobin next and free hemin least, which the authors take to mean that other components of haemoglobin and of blood add inhibition of their own. Adding any of the three lengthened reaction lag times in a dose-dependent way at every seed dilution tested, and at higher concentrations detection was abolished altogether. The paper was posted online on December 18, 2025 and carries a January 14, 2026 issue date; a preprint version was posted to bioRxiv in April 2025.
The mechanism the authors report is the part that matters for anyone hoping to move prion testing into blood. The inhibition did not appear to destroy the misfolded prion seeds in the sample. Instead, hemin was shown to bind the assay's recombinant prion protein substrate in RT-QuIC buffer, and both hemin and haemoglobin changed that substrate's solubility. When the team ran haem-free reactions with deliberately reduced substrate, from 0.01 to 0.10 mg/mL against a standard 0.1 mg/mL, reactions below 0.05 mg/mL produced the same picture: longer lag times, lost detections and weaker fluorescence. Raising the starting substrate concentration rescued detection in haemoglobin-inhibited reactions. On that evidence the authors conclude the assay fails because its substrate is being used up, not because the prions are gone.
The study also put numbers on where that matters. Measuring total haem in a range of small ruminant tissues by oxalic acid fluorescence assay, the authors found that nearly all intact tissues contained more than 200 micromolar haem. RT-QuIC practice is commonly to dilute a tissue sample 1,000-fold before testing, and at that dilution only blood, spleen and placenta still approached inhibitory levels; whole blood was one of the few notable exceptions to the rule that a 1:1,000 dilution clears the problem. The authors write that heme-mediated inhibition is unlikely to be more than a minimal factor at a 1,000-fold dilution or greater, while cautioning that several tissues retain micromolar haem at a 100-fold dilution, which could still disrupt detection where prion levels are low, as in peripheral tissues or early infection. That is the trade the paper exposes rather than resolves: dilute enough to escape the inhibitor and you may also dilute the seed below detection.
The work is in vitro chemistry using animal material, and its stated purpose is scrapie and chronic wasting disease control, not human diagnosis. It should be read against evidence that blood assays are not impossible in prion disease: a study in Blood in October 2024, led by groups in Glasgow, Montpellier and Toulouse, reported that three in vitro assays detected prion infection in blood samples from BSE-infected sheep up to 26 months before clinical signs, with 100 percent specificity, and that the tests worked on human variant CJD brain material. Those assays used pre-analytical steps to concentrate or purify the target before amplification. The Journal of Clinical Microbiology paper offers a reason such steps keep being necessary, and a measurable target for anyone designing them.